Physician profile
John A Purcell
NPI 1235133505
$2,626.24
in general payments reported to CMS, 2019-2025
24 companies · $34.49 in 2025
The $34.49 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,321 · 2020: $237 · 2022: $356 · 2023: $379 · 2024: $297 · 2025: $34.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.44 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $499.29 | 2019-2023 | Rybelsus |
| Sanofi-Aventis U.S. LLC | $271.43 | 2019-2020 | |
| Abbott Laboratories | $248.94 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $224.81 | 2019-2020 | |
| Corcept Therapeutics | $172.80 | 2022-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $164.25 | 2019-2020 | |
| Mannkind Corporation | $139.24 | 2019-2024 | Afrezza |
| Ascensia Diabetes Care US INC. | $127.53 | 2024 | |
| Abbvie INC. | $112.25 | 2019-2022 | |
| Dexcom, INC. | $90.52 | 2019-2023 | Dexcom G6 Transmitter |
| Shire North American Group INC | $89.09 | 2019 | |
| Insulet Corporation | $81.44 | 2024 | Omnipod |
| Ipsen Biopharmaceuticals, INC | $64.92 | 2019 | |
| Ibsa Pharma INC. | $53.34 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $50.64 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $49.47 | 2019 | |
| Tandem Diabetes Care, INC. | $41.58 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $30.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.06 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $22.41 | 2019 | |
| Lilly USA, LLC | $17.64 | 2024 | Jardiance |
| Medtronic Minimed, INC. | $17.17 | 2019 | |
| Becton, Dickinson and Company | $14.60 | 2019 | |
| Companion Medical, INC. | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Purcell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.